Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.40 |
| ▸ | FABP7 | O15540 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | MDM4 | O15151 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28755697 | 0.85 | FABP5 (0.45) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL4858554 | 0.80 | KMT2A (0.44) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL9171084 | 0.77 | KMT2A (0.45) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL1251666 | 0.76 | KMT2A (0.44) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL3195566 | 0.72 | FABP5 (0.47) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL1250338 | 0.72 | FABP5 (0.47) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL6346119 | 0.72 | FABP5 (0.48) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL3220033 | 0.72 | FABP5 (0.48) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL1157567 | 0.72 | FABP5 (0.49) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL30662743 | 0.72 | FABP5 (0.49) | KMT2AFABP5FABP7EPHX2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11396527-B2 | Dual mass spectrometry-cleavable crosslinking reagents for protein-protein interactions | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-07-26 | — | — | US | disclosed |
| US-20200392498-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | SOLSTICE BIOLOGICS LTD (IE) | 2020-12-17 | — | — | US | disclosed |
| US-20200354403-A1 | DUAL MASS SPECTOMETRY-CLEAVABLE CROSSLINKING REAGENTS FOR PROTEIN-PROTEIN INTERACTIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2020-11-12 | — | — | US | disclosed |
| US-10752655-B2 | Dual mass spectrometry-cleavable crosslinking reagents for protein-protein interactions | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-08-25 | — | — | US | disclosed |
| US-20180346505-A1 | MONONUCLEOTIDES HAVING A BIOREVERSIBLE DISULFIDE GROUP | SOLSTICE BIOLOGICS LTD (IE) | 2018-12-06 | — | — | US | disclosed |
| CN-107530369-A | Mononucleotides with bioreversible dithio groups | 索尔斯蒂斯生物有限公司 | 2018-01-02 | — | — | CN | disclosed |
| EP-3229815-A2 | MONONUCLEOTIDES HAVING A BIOREVERSIBLE DISULFIDE GROUP | Solstice Biologics, Ltd. (IE) | 2017-10-18 | — | — | EP | disclosed |
| US-20170114341-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | BRADSHAW CURT W (US) | 2017-04-27 | — | — | US | disclosed |
| EP-3152308-A2 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | Solstice Biologics, Ltd. (IE) | 2017-04-12 | — | — | EP | disclosed |
| EP-3066105-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING DISULFIDE GROUPS | Solstice Biologics, Ltd. (IE) | 2016-09-14 | — | — | EP | disclosed |
| WO-2016094677-A2 | MONONUCLEOTIDES HAVING A BIOREVERSIBLE DISULFIDE GROUP | SOLSTICE BIOLOGICS, LTD. (IE) | 2016-06-16 | — | — | WO | disclosed |
| WO-2015188197-A2 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | SOLSTICE BIOLOGICS, LTD. (IE) | 2015-12-10 | — | — | WO | disclosed |
| WO-2015069932-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING DISULFIDE GROUPS | SOLSTICE BIOLOGICS, LTD. (IE) | 2015-05-14 | — | — | WO | disclosed |
| EP-2528622-A2 | INFLUENZA VIRUS EPITOPES TEMPLATED INTO DOUBLE-STRANDED COILED COILS AND USE THEREOF IN IMMUNIZATION | The Regents of the University of Colorado (US) | 2012-12-05 | — | — | EP | disclosed |
| US-20120014972-A1 | INFLUENZA VIRUS COMPOSITIONS AND METHODS FOR UNIVERSAL VACCINES | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2012-01-19 | — | — | US | disclosed |
| WO-2011094363-A2 | INFLUENZA VIRUS COMPOSITIONS AND METHODS FOR UNIVERSAL VACCINES | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2011-08-04 | — | — | WO | disclosed |
| EP-1934251-B1 | INTERLEUKIN-8 LABELLED VIA ONE OR MORE SITE SPECIFICALLY CONJUGATED HYDRAZINONICOTINAMIDE (HYNIC) MOIETIES AND ITS USE IN DIAGNOSIS OF INFECTION AND INFLAMMATION | STICHTING KATHOLIEKE UNIV (NL) | 2010-06-16 | — | — | EP | disclosed |
| US-20080233084-A1 | Interleukin-8 Labelled Via One or More Site Specifically Conjugated Hydrazinonicotinamide (Hynic) Moieties and its Use in Diagnosis of Infection and Inflammation | STICHTING KATHOLIEKE UNIVERSITEIT OF NIJMEGEN (NL) | 2008-09-25 | — | — | US | disclosed |
| EP-1934251-A2 | INTERLEUKIN-8 LABELLED VIA ONE OR MORE SITE SPECIFICALLY CONJUGATED HYDRAZINONICOTINAMIDE (HYNIC) MOIETIES AND ITS USE IN DIAGNOSIS OF INFECTION AND INFLAMMATION | Stichting Katholieke Universiteit (NL) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007042946-A2 | INTERLEUKIN-8 LABELLED VIA ONE OR MORE SITE SPECIFICALLY CONJUGATED HYDRAZINONICOTINAMIDE (HYNIC) MOIETIES AND ITS USE IN DIAGNOSIS OF INFECTION AND INFLAMMATION | STICHTING KATHOLIEKE UNIVERSITEIT (NL) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120014972-A1 | INFLUENZA VIRUS COMPOSITIONS AND METHODS FOR UNIVERSAL VACCINES | CD81, HAVCR2, CD63 | KMT2A 1459/4885FABP5 1718/4885FABP7 3168/4885 |
| US-20200392498-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | HNRNPC, RNASE1, NSUN3 | KMT2A 3810/4885FABP5 2398/4885FABP7 3658/4885 |
| US-11396527-B2 | Dual mass spectrometry-cleavable crosslinking reagents for protein-protein interactions | TIMCC, DCLRE1A, MTCL3 | KMT2A 2994/4885FABP5 1150/4885FABP7 1377/4885 |
| US-20180346505-A1 | MONONUCLEOTIDES HAVING A BIOREVERSIBLE DISULFIDE GROUP | HCCS, PNP, NT5C3B | KMT2A 1969/4885FABP5 2764/4885FABP7 4769/4885 |
| US-20170114341-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | HNRNPC, RNASE1, NSUN3 | KMT2A 3810/4885FABP5 2398/4885FABP7 3658/4885 |
| US-10752655-B2 | Dual mass spectrometry-cleavable crosslinking reagents for protein-protein interactions | TIMCC, DCLRE1A, MTCL3 | KMT2A 2994/4885FABP5 1150/4885FABP7 1377/4885 |
| US-20200354403-A1 | DUAL MASS SPECTOMETRY-CLEAVABLE CROSSLINKING REAGENTS FOR PROTEIN-PROTEIN INTERACTIONS | TIMCC, MTCL3, DCLRE1A | KMT2A 3716/4885FABP5 800/4885FABP7 1054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.